Domov › Akutna mieločna levkemija › Alabama › Birmingham
Klinične študije za Akutna mieločna levkemija v Birmingham, AL
21 študij za Akutna mieločna levkemija išče udeležence na lokacijah v Birmingham in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Vključevanje udeležencevFaza 2
- University of Alabama at Birmingham Cancer Center, Birmingham
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
Vključevanje udeležencevFaza 1
- Children's Hospital of Alabama, Birmingham
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Vključevanje udeležencevFaza 2
- University of Alabama at Birmingham Cancer Center, Birmingham
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Vključevanje udeležencevFaza 3
- University of Alabama at Birmingham, Birmingham
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Vključevanje udeležencevFaza 2
- University of Alabama at Birmingham Cancer Center, Birmingham
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Vključevanje udeležencevFaza 2
- University of Alabama at Birmingham Cancer Center, Birmingham
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Vključevanje udeležencevFaza 3
- Children's Hospital of Alabama, Birmingham
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Vključevanje udeležencevFaza 2
- University of Alabama - Birmingham, Birmingham
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Vključevanje udeležencevFaza 3
- Children's Hospital of Alabama, Birmingham
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Vključevanje udeležencevFaza 1/2
- O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Vključevanje udeležencevFaza 1/2
- Children's Hospital of Alabama, Birmingham
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Vključevanje udeležencevFaza 2/3
- University of Alabama Birmingham, Birmingham
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Vključevanje udeležencevOpazovalna študija
- University of Alabama at Birmingham, Birmingham
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
Vključevanje udeležencev
- University of Alabama at Birmingham, Division of Hematology and Oncology, Birmingham
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Vključevanje udeležencevFaza 2
- University of Alabama Birmingham, Birmingham
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
Vključevanje udeležencevFaza 1
- University of Alabama at Birmingham, Birmingham
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Vključevanje udeležencevFaza 1
- University of Alabama O'Neal Cancer Center, Birmingham
HPC Offered for PRESERVE Expansion
Vključevanje udeležencevOpazovalna študija
- University of Alabama, Birmingham, Birmingham
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Vključevanje udeležencevFaza 1/2
- The Kirklin Clinic of UAB Hospital, Birmingham
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Vključevanje udeležencevVabljeni zdravi prostovoljci
- University of Alabama - Birmingham, Birmingham
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Vključevanje udeležencevFaza 1
- University of Alabama at Birmingham, Birmingham
Študije za Akutna mieločna levkemija v drugih mestih
- Houston, TX85 študij
- New York City, NY51 študij
- Boston, MA44 študij
- Seattle, WA41 študij
- Baldwin Park, CA40 študij
- Columbus, OH35 študij
- Philadelphia, PA34 študij
- Durham, NC33 študij
- Atlanta, GA31 študij
- Tampa, FL29 študij
- Chicago, IL26 študij
- Portland, OR25 študij
Druge študije v Birmingham
- Rak (vse vrste)31 študij
- Rak dojke24 študij
- Rak jajčnikov23 študij
- Debelost23 študij
- Nemalicelični pljučni rak22 študij
- Množni mielom18 študij
- BOPC17 študij
- Srčno-žilne bolezni17 študij
- Sladkorna bolezen tipa 216 študij
- Rak endometrija16 študij
- Prekomerna telesna teža16 študij
- Cistična fibroza16 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.